Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

NCT07416409 · clinicaltrials.gov ↗

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms
Oncology
HER2-positive Breast Cancer
Metastatic Breast Cancer

Interventions

DRUG: Trastuzumab (Single-Agent Anti-HER2 Therapy)
DRUG: Combination Anti-HER2 Therapy (Trastuzumab + Pertuzumab or Lapatinib)

Sponsor

Deraya University